Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Lancet Oncol
    April 2026
  1. GREGORC V, Majem M, Lo Russo G, Maio M, et al
    Fulzerasib plus cetuximab in first-line KRAS(G12C)-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.
    Lancet Oncol. 2026;27:432-441.
    >> Share

  2. EL SAADANY T, Sacher A
    KRAS(G12C) inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path.
    Lancet Oncol. 2026;27:396-397.
    >> Share

  3. GORRIA T, Mezquita L
    Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer.
    Lancet Oncol. 2026;27:394-395.
    >> Share

    March 2026
  4. ZHONG H, Wang J, Yang R, Luo Y, et al
    Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026 Mar 10:S1470-2045(26)00049.
    >> Share

  5. LEONHARDT CS, Adham M, Bazarbashi S, Ben-Aharon I, et al
    The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer.
    Lancet Oncol. 2026;27:e141-e149.
    >> Share

  6. KIM Y, Bates JE, Yoon HI, Grassberger C, et al
    Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review.
    Lancet Oncol. 2026;27:e130-e140.
    >> Share

    February 2026
  7. GOURD E
    FDA fast-tracks first inhalable gene therapy for lung cancer.
    Lancet Oncol. 2026 Feb 19:S1470-2045(26)00083.
    >> Share

  8. CASASSUS B
    France plans national targeted lung cancer screening.
    Lancet Oncol. 2026 Feb 12:S1470-2045(26)00070.
    >> Share

  9. DE RUYSSCHER D, Damen PJJ, Hendriks LEL, Saw SPL, et al
    Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment.
    Lancet Oncol. 2026;27:155-158.
    >> Share

    January 2026
  10. ZHANG L, Zhang X, Wu L, Xing W, et al
    Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026 Jan 12:S1470-2045(25)00643.
    >> Share

    December 2025
  11. WU YL, Yao Y, Yang JJ, Wu L, et al
    Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
    Lancet Oncol. 2025 Dec 6:S1470-2045(25)00594.
    >> Share

  12. DOUMA LH, van der Noort V, Lalezari F, de Vries JF, et al
    Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
    Lancet Oncol. 2025;26:1676-1684.
    >> Share

    November 2025
  13. ROBBINS HA, Johansson M
    Defining eligibility for lung cancer screening based on individual risk.
    Lancet Oncol. 2025 Nov 10:S1470-2045(25)00537.
    >> Share

  14. VOGEL-CLAUSSEN J, Bollmann BA, May K, Stiebeler S, et al
    Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study.
    Lancet Oncol. 2025 Nov 10:S1470-2045(25)00490.
    >> Share

  15. FUEREDER T, Garde-Noguera J, Garcia-Mosquera JJ, Ruiz-Borrego M, et al
    Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:1454-1466.
    >> Share

    October 2025
  16. NADAL E, Navarro-Martin A
    Radiotherapy-free approach in inoperable locally advanced non-small-cell lung cancer: are we ready for this shift?
    Lancet Oncol. 2025 Oct 10:S1470-2045(25)00485.
    >> Share

  17. HATA A, Ninomaru T, Okada H, Kogure Y, et al
    Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2025 Oct 10:S1470-2045(25)00462.
    >> Share

  18. DI FEDERICO A, Wang K, Chen MF, Barsouk AA, et al
    First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
    Lancet Oncol. 2025;26:1357-1369.
    >> Share

    September 2025
  19. DI FEDERICO A, Stumpo S, Mantuano F, De Giglio A, et al
    Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
    Lancet Oncol. 2025 Sep 29:S1470-2045(25)00429.
    >> Share

  20. COLLINGRIDGE D
    2025 World Conference on Lung Cancer.
    Lancet Oncol. 2025 Sep 11:S1470-2045(25)00548.
    >> Share

  21. PAULSON KG, Lau SCM, Ahn MJ, Moskovitz M, et al
    Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
    Lancet Oncol. 2025 Sep 8:S1470-2045(25)00480.
    >> Share

    June 2025
  22. ZHOU C, Wang Z, Sun M, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2025 Jun 13:S1470-2045(25)00198.
    >> Share

    March 2025
  23. BHAMANI A, Creamer A, Verghese P, Prendecki R, et al
    Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
    Lancet Oncol. 2025 Mar 25:S1470-2045(25)00082.
    >> Share

  24. HEUVELMANS MA
    Lung cancer screening implementation: turning evidence into practice.
    Lancet Oncol. 2025 Mar 25:S1470-2045(25)00138.
    >> Share

  25. GOURD E
    Lung cancer treatment compromised by delayed genomic test results.
    Lancet Oncol. 2025 Mar 13:S1470-2045(25)00149.
    >> Share

    February 2025
  26. LI Z, Wang Y, Sun Y, Wang L, et al
    Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
    Lancet Oncol. 2025 Feb 25:S1470-2045(25)00012.
    >> Share

    January 2025
  27. SEN T, Dotsu Y, Corbett V, Puri S, et al
    Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.
    Lancet Oncol. 2025;26:e13-e33.
    >> Share

  28. XU Y, Chen K, Xu Y, Li H, et al
    Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:74-84.
    >> Share

    December 2024
  29. ZHAO Y, Xiong S, Ren Q, Wang J, et al
    Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.
    Lancet Oncol. 2024 Dec 6:S1470-2045(24)00599.
    >> Share

    November 2024
  30. GOURD E
    Lung cancer rates highest among British Bangladeshi men.
    Lancet Oncol. 2024 Nov 28:S1470-2045(24)00683.
    >> Share

  31. HEINZERLING JH, Mileham KF, Robinson MM, Symanowski JT, et al
    Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2024 Nov 27:S1470-2045(24)00573.
    >> Share

  32. FURLOW B
    American Lung Association calls for expanded insurance coverage for lung cancer screening.
    Lancet Oncol. 2024 Nov 21:S1470-2045(24)00670.
    >> Share

  33. THUREAU S, Giraud P, Zalcman G, Vera P, et al
    [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2024;25:e541.
    >> Share

  34. BOWEN JONES S, Cooke S, Belderbos J, Faivre-Finn C, et al
    [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e540.
    >> Share

  35. XU X, Ye L, Shi J, Li H, et al
    [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e539.
    >> Share

    October 2024
  36. PROVENCIO M, Nadal E, Insa A, Garcia Campelo R, et al
    Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2024 Oct 14:S1470-2045(24)00498.
    >> Share

  37. WOLF J, Hochmair M, Han JY, Reguart N, et al
    Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
    Lancet Oncol. 2024;25:1357-1370.
    >> Share

    August 2024
  38. GOURD E
    World's first lung cancer vaccine trial launched in the UK.
    Lancet Oncol. 2024 Aug 30:S1470-2045(24)00324.
    >> Share

  39. ZHAO Y, He Y, Wang W, Cai Q, et al
    Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Lancet Oncol. 2024 Aug 16:S1470-2045(24)00379.
    >> Share

  40. VERA P, Thureau S, Le Tinier F, Chaumet-Riffaud P, et al
    Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 t
    Lancet Oncol. 2024 Aug 9:S1470-2045(24)00320.
    >> Share

  41. WU YL, Guarneri V, Voon PJ, Lim BK, et al
    Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2024;25:989-1002.
    >> Share

  42. TENDLER S, Dunphy MP, Agee M, O'Donoghue J, et al
    Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
    Lancet Oncol. 2024;25:1015-1024.
    >> Share

    July 2024
  43. LAZARATOS AM, Petrecca K, Guiot MC, Jerzak KJ, et al
    CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e282.
    >> Share

  44. AERTS JG, Belderbos R, Baas P, Scherpereel A, et al
    Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase
    Lancet Oncol. 2024;25:865-878.
    >> Share

  45. ZAUDERER MG, Dagogo-Jack I
    Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial.
    Lancet Oncol. 2024;25:825-827.
    >> Share

    June 2024
  46. CHEN L, Zhu XZ, Zhao SJ, Yang QW, et al
    PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
    Lancet Oncol. 2024;25:e233.
    >> Share

    May 2024
  47. BURKI T
    EPA ruling to ban chrysotile asbestos.
    Lancet Oncol. 2024;25:537.
    >> Share

    April 2024
  48. SMIT EF, Felip E, Uprety D, Nagasaka M, et al
    Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Lancet Oncol. 2024;25:439-454.
    >> Share

    March 2024
  49. GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al
    Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
    Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040.
    >> Share

    February 2024
  50. RHA SY, Bordia S
    Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.
    Lancet Oncol. 2024;25:e52.
    >> Share

  51. SCHUTTE T, Derks S, van Laarhoven HWM
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e51.
    >> Share

  52. HUANG CY, Wu XB
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e50.
    >> Share

    January 2024
  53. RASHID T, Bennett JE, Muller DC, Cross AJ, et al
    Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.
    Lancet Oncol. 2024;25:86-98.
    >> Share

    December 2023
  54. LEAL T, Langer C
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2023;24:e454.
    >> Share

  55. OLIVIER T, Addeo A
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer.
    Lancet Oncol. 2023;24:e453.
    >> Share

  56. FURLOW B
    IASLC calls for clinical trials to use tobacco use data.
    Lancet Oncol. 2023;24:1309.
    >> Share

    November 2023
  57. SCOTT SE, Gildea C, Nicholson BD, Evans RE, et al
    Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
    Lancet Oncol. 2023;24:1242-1251.
    >> Share

  58. DOUMA LH, Lalezari F, van der Noort V, de Vries JF, et al
    Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
    Lancet Oncol. 2023;24:1219-1228.
    >> Share

    October 2023
  59. COOPER WA
    Lessons and opportunities from improved understanding of global lung cancer histological subtypes.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00475.
    >> Share

  60. ZHANG Y, Vaccarella S, Morgan E, Li M, et al
    Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00444.
    >> Share

  61. HU X, Wang C, Huang W, Barber SM, et al
    Pembrolizumab monotherapy for advanced chordoma.
    Lancet Oncol. 2023;24:e399.
    >> Share

    September 2023
  62. FENNELL DA
    Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2023;24:946-947.
    >> Share

  63. LEAL T, Kotecha R, Ramlau R, Zhang L, et al
    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 st
    Lancet Oncol. 2023;24:1002-1017.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016